Endocrine Today Current Issue
The following articles appeared in the print edition of Endocrine Today.
Table of Contents
- FDA guidelines to quantify CHD risk in diabetes products: a good idea?
-
- Hyperthyroidism — back to basics Ronald Tamler, MD, PhD, MBA
- A call for standardized self-monitoring blood glucose education Mary M. Austin
- Understanding alternatives for estrogen preparations Eileen Durham, C-PNP, MSN, RN
- Preventing diabetic ketoacidosis requires community-based advocacy Henry J. Rohrs, MD
- A complicated case of Paget’s disease of the bone Stephanie L. Lee, MD, PhD, ECNU; Daniel J. Rubin, MD
- FIELD: Fenofibrate reduced CVD risk among patients with type 2 diabetes, metabolic syndrome
- SEARCH: Youth with type 1 diabetes, short disease duration had abnormal lipid, lipoprotein profiles
- Type 2 diabetes and surgery: band or bypass? Brant K. Oelschlager, MD; Saurabh Khandelwal, MD
-
- Insulin absorption: a factor affecting variability in glycemic response June Felice Johnson, BS, PharmD, FASHP, CDM-diabetes
- Does the FDA’s recommendation regarding CV risk potential in type 2 diabetes drugs seem reasonable?